Faeth Therapeutics
FTH
39 hedge funds and large institutions have $7.06M invested in Faeth Therapeutics in 2022 Q2 according to their latest regulatory filings, with 10 funds opening new positions, 7 increasing their positions, 16 reducing their positions, and 12 closing their positions.
0.07% less ownership
Funds ownership: 0.58% → 0.51% (-0.07%)
7% less funds holding
Funds holding: 42 → 39 (-3)
14% less capital invested
Capital invested by funds: $8.21M → $7.06M (-$1.15M)
17% less first-time investments, than exits
New positions opened: 10 | Existing positions closed: 12
56% less repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 16
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCM
RA Capital Management
Boston,
Massachusetts
|
+$1.36M |
| 2 |
NM
Newtyn Management
New York
|
+$778K |
| 3 |
Renaissance Technologies
New York
|
+$307K |
| 4 |
E
Ergoteles
New York
|
+$175K |
| 5 |
Millennium Management
New York
|
+$157K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
-$1.85M |
| 2 |
State Street
Boston,
Massachusetts
|
-$374K |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
-$307K |
| 4 |
JP Morgan Chase
New York
|
-$291K |
| 5 |
Northern Trust
Chicago,
Illinois
|
-$260K |
FTH Hedge Fund Activity: Q2 2022 in Review
39 of the 5,937 institutional investors tracked by Wall St. Rank reported a position in Faeth Therapeutics (FTH) for Q2 2022, worth a combined $7.06M — down 14% from $8.21M a quarter earlier.
Sellers outnumbered buyers: 12 funds closed out of FTH and 10 opened new positions — a net loss of 2 holders — while 16 trimmed existing stakes and 7 added.
The largest buyer was RA Capital Management, opening a new position worth an estimated $1.36M. The largest seller was BlackRock, cutting an estimated $1.85M.
- 39 institutional investors held Faeth Therapeutics (FTH) as of Q2 2022, down from 42 in Q1 2022.
- Funds reported $7.06M of Faeth Therapeutics stock for Q2 2022, down 14% quarter-over-quarter.
- 10 funds opened new Faeth Therapeutics positions in Q2 2022 and 12 closed out, a net change of -2 holders.
- The largest Faeth Therapeutics buyer in Q2 2022 was RA Capital Management, an estimated $1.36M added.
- The largest Faeth Therapeutics seller in Q2 2022 was BlackRock, an estimated $1.85M sold.
Based on aggregated 13F filings for Q2 2022.